Beverly, MA – According to filings with the U.S. Securities and Exchange Commission, LexaGene is raising $1,659,999.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Jeffrey Mitchell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LexaGene

LexaGene is a molecular diagnostics company developing a fully automated, rapid pathogen detection system for use at the point-of-need where samples are collected, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. LexaGene’s MiQLab system aims to transform pathogen detection in multi-billion-dollar-markets, namely human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access markets that need critical answers in less time.

To learn more about LexaGene, visit http://lexagene.com/

Contact:
Jeffrey Mitchell, Chief Financial Officer
800-215-1824
jeffreymitchell@lexagene.com
https://www.linkedin.com/in/jeffrey-mitchell-41087a8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved